[20]
|
50
|
50
|
Male (n=24)
Female (n=26)
|
M+A or A
|
16.5
|
IV
|
Not recorded
|
M+A=48% a
A=48% a
|
10.6
|
NA
|
2.6 months
|
[7]
|
47
|
28
|
Male (n=10)
Female (n=18)
|
M+E+D+C
|
NA
|
II (n=2)
III (n=6)
IV (n=20)
|
Not recorded
|
53.5%b
|
NA
|
NA
|
NA
|
[21]
|
50
|
72
|
Male (n=24)
Female (n=48)
|
M+E+D+C
|
120
|
I (n=1)
II (n=24)
III (n=30)
IV (n=17)
|
Not recorded
|
48.6% b
|
Male=23.6
Female=38.6
|
≤2 years=26.4 months
≥2 years=51.7 months
|
NA
|
[18]
|
50
|
304
|
Male (n=121)
Female (n=183)
|
M+E+D+CM+Sz c
M+SzM+E+D+C c
|
78
|
III (n=1)
IV (n=303)
|
14-20
|
First-line therapy: M+E+D+C=23.2% a
M+Sz=9.2% a
|
First-line therapy:
M+E+D+C=14.8
M+Sz=12
|
NA
|
First-line therapy:
M+E+D+C=5 months
M+Sz=2.1 months
Second-line therapy:
M+E+D+CM+Sz=5.6 months
M+SzM+E+D+C=2.2 months
|
[22]
|
54
|
37
|
Male (n=19)
Female (n=18)
|
M+C
|
NA
|
IV
|
Not recorded
|
30% d
|
11.8
|
NA
|
NA
|
[23]
|
46.5
|
45
|
Male (n=23)
Female (n=22)
|
E+C
E+CM (n=16) e
|
NA
|
III (n=2)
IV (n=43)
|
Not recorded
|
13% f
|
10
|
NA
|
NA
|
[19]
|
44.4
|
36
|
Male (n=11)
Female (n=25)
|
M+E+D+V
|
34.8
|
IV
|
10–15
|
22% g
|
13.5
|
NA
|
NA
|